Related Experiment Video
Updated: Aug 26, 2026
Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells
Published on: February 2, 2011
Expansion of human Valpha24+ NKT cells by repeated stimulation with KRN7000
Paul R Rogers1, Atsushi Matsumoto, Olga Naidenko
1Research Laboratory, Gemini Science, Inc., 10355 Science Center Drive, San Diego, CA, 92121, USA. progers@liai.org
Abstract:
Changes in Valpha24+Vbeta11+ NKT cell number and function are associated with human autoimmune diseases and cancer. Restoration of this corresponding NKT cell population in mice or in vivo activation with alpha-galactosylceramide (KRN7000) can prevent or reduce tumor growth and autoimmunity. Although the therapeutic value of these natural killer T (NKT) cells in man remains to be determined, large numbers of functional antigen-specific NKT cells can be expanded in vitro. We show that Valpha24+Vbeta11+ human NKT cells are expanded by repeated stimulation with KRN7000, unfractionated donor peripheral blood mononuclear cells (PBMC), and recombinant human interleukin-2 (rhIL-2). NKT cells were expanded continuously for more than 2 months with a potential yield of >10(12) cells. The expanded NKT cells retained their CD4+ or CD4- phenotype after restimulation and were functional as shown by cytokine secretion, killing of antigen-pulsed target cells, and activation of NK cell cytotoxicity. This expansion method may be useful for proof-of-concept studies involving adoptive transfer of ex vivo-expanded NKT cells as a new therapeutic option for cancer and autoimmune diseases.
Insights
Researchers expanded Valpha24+Vbeta11+ natural killer T (NKT) cells in vitro for over two months. This method yields large numbers of functional NKT cells, potentially aiding cancer and autoimmune disease therapies.
Area of Science:
- Immunology
- Cell Biology
- Therapeutic Development
Background:
- Valpha24+Vbeta11+ natural killer T (NKT) cells play a role in human autoimmune diseases and cancer.
- In vivo administration of alpha-galactosylceramide (KRN7000) or NKT cell restoration in mice can mitigate tumor growth and autoimmunity.
Purpose of the Study:
- To develop an in vitro expansion method for generating large quantities of functional Valpha24+Vbeta11+ human NKT cells.
- To assess the feasibility of using ex vivo-expanded NKT cells for therapeutic applications.
Main Methods:
- Repeated stimulation of Valpha24+Vbeta11+ human NKT cells using KRN7000, peripheral blood mononuclear cells (PBMC), and recombinant human interleukin-2 (rhIL-2).
- Continuous expansion for over two months.
- Functional assessment including cytokine secretion, target cell killing, and NK cell cytotoxicity activation.
Main Results:
- Sustained expansion of Valpha24+Vbeta11+ NKT cells exceeding 10^12 cells over two months.
- Expanded NKT cells maintained their CD4+ or CD4- phenotype.
- Demonstrated functionality through cytokine release, antigen-specific cytotoxicity, and enhanced NK cell activity.
Conclusions:
- An effective in vitro method for expanding large numbers of functional Valpha24+Vbeta11+ human NKT cells was established.
- This expansion technique may support proof-of-concept studies for adoptive NKT cell transfer in treating cancer and autoimmune diseases.
